SEARCH

SEARCH BY CITATION

References

  • Adler, J. R., M. B. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, et al. 2011. ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomuopathy. J. Am. Coll. Cardiol. 58:212260.
  • Ardiansyah, Y. Ohsaki, H. Shirakawa, T. Koseki, and M. Komai. 2008. Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. J. Agric. Food Chem. 56:28252830.
  • Cao, Z., and Y. Li. 2004. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489:3948.
  • De Caterina, R., A. Zampolli, S. Del Turco, R. Madonna, and M. Massaro. 2006. Nutritional mechanisms that influence cardiovascular disease. Am. J. Clin. Nutr. 83:421S426S.
  • De Luca, L., A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. Voors, et al. 2008. Overview of emerging pharmacologic agents for acute heart failure syndromes. Eur. J. Heart Fail. 10:201213.
  • DeMarco, V. G., M. S. Johnson, A. T. Whaley-Connell, and J. R. Sowers. 2010. Cytokine abnormalities in the etiology of the cardiometabolic syndrome. Curr. Hypertens. Rep. 12:9398.
  • Dolinsky, V. W., A. Y. Chan, I. Robillard Frayne, P. E. Light, C. Des Rosiers, and J. R. Dyck. 2009. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 119:16431652.
  • Forstermann, U. 2010. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 459:923939.
  • Frey, N., and E. N. Olson. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:4579.
  • Giordano, F. J. 2005. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115:500508.
  • Gomez-Arroyo, J., S. Mizuno, K. Szczepanek, B. Van Tassell, N. Ramesh, and C. G. Dos Remedios. 2013. Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ. Heart Fail 6:136144.
  • Guha, P., A. Dey, B. Sarkar, M. V. Dhyani, and S. K. Brandyopadhyay. 2009. Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice. J. Pharmacol. Exp. Ther. 328:829838.
  • Hung, L. M., M. J. Su, W. K. Chu, C. W. Chiao, W. F. Chan, and J. K. Chen. 2002. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol. 135:16271633.
  • Juric, D., P. Wojciechowski, D. K. Das and T. Netticadan. 2007. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am. J. Physiol. Heart Circ. Physiol. 292:H2138H2143.
  • Kalra, E. K. 2003. Nutraceutical–definition and introduction. AAPS PharmSci. 5:E25.
  • Kang, S. S., M. Cuendet, D. C. Endringer, V. L. Croy, J. M. Pezzuto, and M. A. Lipton. 2009. Synthesis and biological evaluation of a library of resveratrol analogues as inhibitors of COX-1, COX-2 and NF-kappaB. Bioorg. Med. Chem. 17:10441054.
  • Karlsen, A., I. Paur, S. K. Bohn, A. K. Sakthi, G. I. Borge, M. Serafini, et al. 2010. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur. J. Nutr. 49:345355.
  • Kroon, P. A., A. Iyer, P. Chunduri, V. Chan, and L. Brown. 2010. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr. Med. Chem. 17:24422455.
  • Lagouge, M., C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, et al. 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:11091122.
  • Leiro, J., J. A. Arranz, N. Fraiz, M. L. Sanmartin, E. Quezada, and F. Orallo. 2005. Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling. Int. Immunopharmacol. 5:393406.
  • Li, H. L., A. B. Wang, Y. Huang, D. P. Liu, C. Wei, G. M. Williams, et al. 2005. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic. Biol. Med. 38:243257.
  • Li, H., N. Xia, and U. Forstermann. 2012. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26:102110.
  • Li, J., S. P. Levick, D. J. Dipette, J. S. Janicki, and S. C. Supowit. 2013. Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure. Regul. Pept. 185:2028.
  • Liew, C. C., and V. J. Dzau. 2004. Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 5:811825.
  • Matsumori, A., T. Yamada, H. Suzuki, Y. Matoba, and S. Sasayama. 1994. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br. Heart J. 72:561566.
  • Mina, Y., S. Rinkevich-Shop, E. Konen, O. Goitein, T. Kushnir, F. H. Epstein, et al. 2013. Mast cell inhibition attenuates myocardial damage, adverse remodeling, and dysfunction during fulminant myocarditis in the rat. J. Cardiovasc. Pharmacol. Ther. 18:152161.
  • Movahed, A., L. Yu, S. J. Thandapilly, X. L. Louis, and T. Netticadan. 2012. Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury. Arch. Biochem. Biophys. 527:7480.
  • Murdoch, C. E., M. Zhang, A. C. Cave, and A. M. Shah. 2006. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc. Res. 71: 208215.
  • Pfluger, P. T., D. Herranz, S. Velasco-Miguel, M. Serrano, and M. H. Tschöp. 2008. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl Acad. Sci. USA 105:97939798.
  • Ramaa, C. S., A. R. Shirode, A. S. Mundada, and V. J. Kadam. 2006. Nutraceuticals–an emerging era in the treatment and prevention of cardiovascular diseases. Curr. Pharm. Biotechnol. 7:1523.
  • Rimbaud, S., M. Ruiz, J. Piquereau, P. Mateo, D. Fortin, V. Veksler, et al. 2011. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 6:e26391.
  • Rodgers, J. T., C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434:113118.
  • Ruetten, H., S. Dimmler, D. Gehrig, C. Ihling, and A. M. Zeiher. 2006. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc. Res. 66:444453.
  • Schmidt, A. G., J. Zhai, A. N. Carr, M. J. Gerst, J. N. Lorenz, P. Pollesello, et al. 2002. Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovasc. Res. 56: 248259.
  • Seymour, E. M., A. A. Singer, M. R. Bennink, R. V. Parikh, A. Kirakosyan, P. B. Kaufman, et al. 2008. Chronic intake of a phytochemical-enriched diet reduces cardiac fibrosis and diastolic dysfunction caused by prolonged salt-sensitive hypertension. J. Gerontol. A Biol. Sci. Med. Sci. 63:10341042.
  • Sharma, S., K. Chopra, S. K. Kulkarni, and J. N. Agrewala. 2007. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147:155163.
  • Sin, T. K., X. M. Pei, B. T. Teng, E. W. Tam, B. Y. Yung, and P. M. Siu. 2013. Oxidative stress and DNA damage signalling in skeletal muscle in pressure-induced deep tissue injury. Pflugers Arch. 465:295317.
  • Takimoto, E., and D. A. Kass. 2007. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49:241248.
  • Tavares, M., E. Rezlan, I. Vostroknoutova, H. Khouadja, and A. Mebazaa. 2008. New pharmacologic therapies for acute heart failure. Crit. Care Med. 36(1 Suppl.):S112S120.
  • Thandapilly, S. J., P. Wojciechowski, J. Behbahani, X. L. Louis, L. Yu, D. Juric, et al. 2010. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am. J. Hypertens. 23:192196.
  • Tunuguntla, A. 2007. Emerging drug therapies for the management of acute decompensated heart failure. Tenn. Med. 100:3337.
  • Ungvari, Z., N. Labinskyy, P. Mukhopadhyay, J. T. Pinto, Z. Bagi, P. Ballabh, et al. 2009. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 297:H1876H1881.
  • Valko, M., D. Leibfritz, J. Moncol, M. T Cronin, M. Mazur, and J. Telser. 2007. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39:4484.
  • Vaziri, H., S. K. Dessain, E. Ng Eaton, S. I. Imai, R. A. Frye, T. K. Pandita, et al. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149159.
  • Wang, Z., and L.Y. Si. 2013. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor in the cardioprotective effects of intermittent hypoxia in rats. Ups. J. Med. Sci. 118:6574.
  • Wojciechowski, P., D. Juric, X. L. Louis, S. J. Thandapilly, L. Yu, C. Taylor, et al. 2010. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J. Nutr. 140:962968.
  • Wu, J.-H., J. Hagaman, S. Kim, R. L. Reddick, and N. Maeda. 2002. Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arterioscler. Thromb. Vasc. Biol. 22:469475.
  • Xing, Y., T. Niu, W. Wang, J. Li, S. Li, J. S. Janicki, et al. 2012. Triterpenoid dihydro-CDDO-trifluoroethyl amide protects against maladaptive cardiac remodeling and dysfunction in mice: a critical role of Nrf2. PLoS ONE 7:e44899.
  • Yeung, F., J. E. Hoberg, C. S. Ramsey, M. D. Keller, D. R. Jones, R. A. Frye, et al. 2004. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:23692380.
  • Yu, S., and G. Li. 2010. MicroRNA expression and function in cardiac ischemic injury. J. Cardiovasc. Transl. Res. 3:241245.
  • Zhang, P., X. Xu, X. Hu, E. D. van Deel, G. Zhu, and Y. Chen. 2007. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ. Res. 100:10891098.